Table 2.
Summary of the main immunization experiment (n = 10 mice per experimental group) according to vaccine administration mode.
| Experimental group | Formulation | Dose/volume |
|---|---|---|
| Subcutaneous injection | ||
| PBS-SC | PBS solution (control) | 100 µl |
| LeCoVax-2 +Alum-SC | 2 × 107 cells Lt-spike + 10 μg RBD + Alum | 100 µl |
| LeCoVax-2 +AddaVax-SC | 2 × 107 cells Lt-spike + 10 μg RBD + AddaVax | 100 µl |
| RBD+Alum-SC | 20 μg RBD + Alum | 100 µl |
| RBD+AddaVax-SC | 20 μg RBD + AddaVax | 100 µl |
| Rectal administration | ||
| PBS-R | PBS solution (control) | 50 µl |
| LeCoVax-2-R | 1 × 108 cells Lt-spike + 20 μg RBD | 50 µl |
| LeCoVax-2 +R84810-R | 1 × 108 cells Lt-spike + 20 μg RBD + 10 μg R848 | 50 µl |
| LeCoVax-2 +R84825-R | 1 × 108 cells Lt-spike + 20 μg RBD + 25 μg R848 | 50 µl |
| RBD+R84825-R | 20 μg RBD + 25 μg R848 | 50 µl |
| Lt: Leishmania tarentolae; RBD: Receptor Binding Domain; SC: subcutaneous; R: rectal; Alum: aluminium phosphate gel; AddaVax: squalene-based oil-in-water (w/o) nano-emulsion; R848: Resiquimod. | ||